GHRP-2
GHRP-2 is a powerful growth hormone secretagogue that mimics ghrelin (your “hunger hormone”) to stimulate dramatic GH release while also genuinely increasing appetite and food intake—useful for people with wasting, poor appetite, or recovery needs. It activates the same receptor as ghrelin, causing pituitary cells to release stored GH and promote new GH synthesis, creating GH spikes up to 36-fold higher than normal.
Route
Subcutaneous injection
Dose range
100 mcg – 300 mcg
Frequency
Once per day (subcutaneous) at bedtime
Cycle length
8–12 weeks
Overview
GHRP-2 is a powerful growth hormone secretagogue that mimics ghrelin (your “hunger hormone”) to stimulate dramatic GH release while also genuinely increasing appetite and food intake—useful for people with wasting, poor appetite, or recovery needs. It activates the same receptor as ghrelin, causing pituitary cells to release stored GH and promote new GH synthesis, creating GH spikes up to 36-fold higher than normal. Beyond muscle-building effects, studies show GHRP-2 benefits appetite in anorexia nervosa, helps poor nutrition, improves fatigue and gastrointestinal function, and supports people with metabolic challenges or serious illness requiring nutritional recovery.
GHRP-2 stands out for its dual appetite-stimulating and GH-boosting effects, making it valuable for athletes in bulking phases, elderly with declining appetite, or anyone needing to gain weight healthily while building muscle. It improves muscle strength, accelerates tissue repair, and enhances bone density and healing. The downside is increased hunger—ideal if you’re undereating but less so for pure fat loss. Intranasal or injected, clinical safety is excellent with long-term use. For serious muscle gain, post-injury recovery, or combating cachexia (muscle wasting), GHRP-2 offers proven appetite and GH benefits backed by human data.
Studied benefits
- Stimulates a robust release of Growth Hormone (GH) and increases IGF-1 levels
- supports improvements in body composition, metabolic health, recovery, and sleep quality
Reported side effects
- Generally well-tolerated, though it may cause increased appetite, mild water retention, or transient flushing
- Minor injection-site irritation is possible
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
GHRP-2 (5mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~1.67 mg/mL).
Stimulate endogenous growth hormone secretion through ghrelin receptor activation.
GHRP-2 (10mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~3.33 mg/mL).
Support pulsatile GH release for research into body composition, recovery, and sleep quality.
| Week | Daily Dose (mcg) | Draw at 1.67 mg/mL | Log |
|---|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) | + Log |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) | + Log |
| Weeks 5–8 | 200 mcg | 12 units (0.12 mL) | + Log |
| Weeks 9–12 | 250–300 mcg | 18 units (0.18 mL) | + Log |
Frequency
Once per day (subcutaneous) at bedtime.
Timing
Bedtime on an empty stomach; rotate injection sites.
Cycle length
8–12 weeks.
Unit calculator
Set your vial and water; the table above updates.
1.67 mg/mL
50 doses of 100 mcg per vial
At the starting dose (100 mcg × 7/week for a 8-week cycle) you would use about 5.6 mg, i.e. 2 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a high-protein, nutrient-dense diet to support muscle recovery and lean tissue growth while managing the mild appetite stimulation typical of this second-generation secretagogue. Incorporate both resistance and aerobic exercise to utilize the increased growth hormone levels for tissue repair and body composition improvement. Ensure 7–9 hours of quality sleep to facilitate the peak nocturnal GH secretion peaks stimulated by the peptide. Administer on an empty stomach to prevent insulin or dietary fats from blunting the specific signaling at the ghrelin receptors in the pituitary gland.
Evidence
Research summaries
Effect of GHRH and GHRP-2 treatment in vitro on GH, pituitary hormones, and cell morphology in ovine pituitary cell cultures
Findings: Big GH boost with GHRH, balances hormone signals, helps steady release.
Sheep brain cells got GHRP-2 (high dose) and/or GHRH – GH jumped 2x in 30 mins to 2 hours. GHRP-2 cut some calm signals (sst-1/2) but upped GH receivers and Pit-1 (growth boss). Together, mega boost. This shows why docs mix them for max GH without big sides. For short kids or weak adults, it's a reliable pump.
Read the study ↗Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GHRH
Findings: Strong GH spikes alone or double with GHRH, mild other hormone bumps.
In healthy guys, GHRP-2 shots (0.1-1 mcg/kg) spiked GH huge – best at 1 mcg/kg, even more with GHRH. Low doses just GH, high added mild milk hormone and stress hormone rises, no sex or thyroid changes. Synergy means tiny doses work big. Great for GH tests or therapy without overload.
Read the study ↗Growth hormone-releasing peptides and their analogs
Findings: Releases GH in animals/humans, leads to non-peptide versions for easy use.
GHRP-2 (hexapeptide) blasts GH in beasts and people, better than older ones. It sparked non-protein copiers like MK-677 for pills. Works via special receivers, not just GHRH path. Used for growth fails, muscle waste, fat loss. Future: easy meds for low GH life.
Read the study ↗Dose-effect study of intranasal administration of growth hormone releasing hormone-(1-44) in normal young men
Findings: Nose spray GH boost, good for kids' growth trials (links to GHRP synergy).
Though GHRH focus, ties to GHRP-2 pairs. 500 mcg nose GHRH sparked solid GH in young men, less than IV but tolerable. Dose curve showed steady rise. For GHRP-2 combos, easier give without needles. Sets stage for blends in growth therapy.
Read the study ↗Identification
Chemistry
- cas
- 158861-67-7 (primary); also designated as pralmorelin
- formula
- C₄₅H₅₅N₉O₆
- molecular weight
- 817.97-818.0 g/mol
- sequence
- D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ (where 2-Nal = 2-naphthylalanine, D indicates D-amino acids)
- source
- Synthetic; rationally designed as a ghrelin receptor agonist analog
- biosynthesis
- Non-ribosomal; chemically synthesized through peptide bond formation
- type
- Linear peptide; C-terminal amidation; contains both D- and L-amino acids
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
BPC-157, TB-500
- Route
- Subcutaneous
- Dose
- 333 mcg – 667 mcg
- Cycle
- 8–12 weeks
CJC-1295 (No DAC)
No DAC
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 8–12 weeks